Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Versus Autologous FMT for Axial Spondyloarthritis
NCT06451588Phase 2Recruiting
- Sponsor
- University Hospital of North Norway
- Start
- Jun 2024
- Primary completion
- May 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in axial spondyloarthritis (axSpA) (4 arms), sponsored by University Hospital of North Norway. Primary endpoint: Minimal Clinically Important Improvement at 90 days. Started Jun 2024; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT06451588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451588.